Last updated on May 2019

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study


Brief description of study

The purpose of this study is to obtain long term safety and tolerability data of vedolizumab subcutaneous (vedolizumab SC) in participants with ulcerative colitis (UC) and Crohn's disease (CD).

Detailed Study Description

The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to assess its long-term safety and effectiveness in treating participants with UC or CD. This study will look at the long-term side effects and response/remission of UC and CD in participants who received vedolizumab SC in a prior vedolizumab SC study.

The study will enroll up to 692 patients. All participants enrolled in this study will have previously participated in the MLN0002SC-3027 or MLN0002SC-3031 study. Participants who completed the Maintenance Period (Week 52) in their previous study, or who did not achieve a clinical response at Week 6 but who did achieve a clinical response at Week 14 after having received a third vedolizumab IV infusion at Week 6 in their previous study, will receive open-label vedolizumab SC 108 mg, once every 2 weeks (Q2W). Participants who withdrew early from the Maintenance Period of their previous study due to disease worsening or need for rescue medications will receive open-label vedolizumab SC 108 mg, once every week (QW). Participants who experience treatment failure (disease worsening or need for rescue medications while in the current study will be dose escalated to vedolizumab SC 108 mg QW.

This multi-center trial will be conducted worldwide. Participation in this vedolizumab SC study will continue until vedolizumab SC becomes commercially available, the participant withdraws from the study, or the sponsor decides to close the study. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.

Clinical Study Identifier: NCT02620046

Find a site near you

Start Over

Arkansas Primary Care Clinic, PA

Little Rock, AR United States
  Connect »

BRCR Medical Center, Inc.

Pembroke Pines, FL United States
  Connect »

Shafran Gastroenterology Center

Winter Park, FL United States
  Connect »

Florida Medical Clinic, P.A.

Zephyrhills, FL United States
  Connect »

Grand Teton Research Group, PLL

Idaho Falls, ID United States
  Connect »

Carle Foundation Hospital

Urbana, IL United States
  Connect »

Tri-State Gastroenterology Associates

Crestview Hills, KY United States
  Connect »

Research Concierge, LLC

Owensboro, KY United States
  Connect »

Gastroenterology Associates, LLC

Baton Rouge, LA United States
  Connect »

Louisiana Research Center, LLC

Shreveport, LA United States
  Connect »

Mayo Clinic - Rochester

Rochester, MN United States
  Connect »

Digestive Health Center PA

Ocean Springs, MS United States
  Connect »

AGA Clinical Research Associates, LLC

Egg Harbor Township, NJ United States
  Connect »

Options Health Research

Tulsa, OK United States
  Connect »

San Antonio Gastroenterology

San Antonio, TX United States
  Connect »

Hospital Italiano

Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Centro Medico Viamonte SRL

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

Nepean Hospital

Kingswood, Australia
  Connect »

Mater Hospital Brisbane

South Brisbane, Australia
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »

Imeldaziekenhuis

Bonheiden, Belgium
  Connect »

AZ Delta

Roeselare, Belgium
  Connect »

EUGASTRO GmbH

Leipzig, Germany
  Connect »

Kangbuk Samsung Hospital

Seoul, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

NZOZ Vitamed

Bydgoszcz, Poland
  Connect »

Nzoz Vivamed

Warszawa, Poland
  Connect »

LLC "RIAT SPb"

Saint-Petersburg, Russian Federation
  Connect »

Dr CCM Ziady Practice

Pretoria, South Africa
  Connect »

Dr MJ Prins Practice

Cape Town, South Africa
  Connect »

Dr JP Wright Practice

Cape Town, South Africa
  Connect »

CI City Hospital #1

Zaporizhzhia, Ukraine
  Connect »

Royal Free Hospital

London, United Kingdom
  Connect »

St George's Hospital

London, United Kingdom
  Connect »

Royal Shrewsbury Hospital

Shrewsbury, United Kingdom
  Connect »

Royal Wolverhampton hospital

Wolverhampton, United Kingdom
  Connect »